What is Labviva?
Founded in 2017 and headquartered in Boston, MA, Labviva operates as a specialized digital marketplace designed to connect the life science community with essential products. The platform facilitates seamless purchasing experiences by integrating scientific content directly with a wide array of reagents, chemicals, and instrumentation from hundreds of brands and suppliers. This unique synergy between product offerings and scientific context aims to enhance efficiency and accessibility for researchers, positioning Labviva as a key enabler in scientific discovery and development.
How much funding has Labviva raised?
Labviva has raised a total of $28M across 2 funding rounds:
Angel/Seed
$8M
Series A
$20M
Angel/Seed (2021): $8M with participation from B Capital Group, Senator Investment Group, and Glasswing Ventures
Series A (2023): $20M led by Glasswing Ventures, B Capital Group, Senator Investment Group, and Biospring Partners
Key Investors in Labviva
Glasswing Ventures
Glasswing Ventures is a venture capital firm that invests in early-stage companies leveraging AI and frontier technology for enterprise and security markets, offering deep technical expertise to support transformative startups.
B Capital Group
B Capital is a venture capital firm focused on empowering entrepreneurs by investing in early and late-stage companies across Technology, Healthcare, and Climate sectors, managing over $8 billion in assets.
Biospring Partners
Biospring Partners specializes in partnering with technology-enabled pharma services businesses, focusing on innovation in manufacturing and clinical trial services to enhance the life sciences industry.
What's next for Labviva?
The recent major strategic investment in Labviva signals a significant phase of growth and expansion for the company. This capital infusion is expected to fuel further development of its digital marketplace, potentially enhancing its AI-driven capabilities and broadening its supplier and product catalog. Labviva's focus on integrating scientific content with procurement is a strategic advantage, likely enabling deeper penetration into the enterprise-level life science market. Future initiatives may include expanding its service offerings, forging new strategic partnerships, and scaling its operational footprint to meet the evolving demands of the global research community.
See full Labviva company page
